Mark Cobbold is currently the SVP of IO Discovery & Cell Therapy Oncology at AstraZeneca, a position held since 2024. Previously, they served as VP of Oncology Early Discovery at AstraZeneca from 2019 to 2024, and have extensive experience in academic and clinical research, including roles as Associate Professor of Medicine at Harvard University and Associate Professor at Massachusetts General Hospital. Mark is also a scientific co-founder of several companies, including GigaMune and Gritstone Oncology, and held a Reader position in Translational Immunology at the University of Birmingham. Mark earned a PhD in Immunology and Immunotherapy from the University of Birmingham between 2000 and 2003.
This person is not in any teams
This person is not in any offices